Diabetes prevention - From physiology to implementation

Hormone and Metabolic Research

Volumn 38, Issue 7, 2006, Pages 460-464

  Schwarz, Peter E H ^a   Schwarz, J ^a   Bornstein, S R ^a   Schulze, J ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Insulin resistance; Prevention; TUMAINI; Type 2 diabetes

Indexed keywords

ACARBOSE; METFORMIN; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EXERCISE; GLUCOSE TOLERANCE; HEALTH CARE; HUMAN; INSULIN RESISTANCE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HUMANS; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 33748076784     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-947839     Document Type: Article

References (21)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787
2. Valensi P et al. Pre-diabetes essential action: a European perspective. Diabetes Metab 2005; 31: 606-620
3. Haffner SM et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
4. Haffner SM. Can reducing peaks prevent type 2 diabetes: implication from recent diabetes prevention trials. Int J Clin Pract Suppl 2002; 129: 33-39
5. Liebl A et al. Costly type 2 diabetes mellitus. Does diabetes cost 20 billion per year? MMW Fortschr Med 2000; 142: 39-42
6. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med; 2002; 346: 393-403
7. Tuomilehto J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350
8. Chiasson JL et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077
9. Pan XR et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544
10. Snitker S et al. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 2004; 27: 1365-1368
11. Torgerson JS et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161
12. Ramachandran A et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 289-297
13. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346
14. Schwarz P et al. Prevention of type 2 diabetes: what challenges do we have to address. Journal of Public Health 2005; 2: 296-303
15. Azen SP et al. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998; 19: 217-231
16. Sartorelli DS et al. Primary prevention of type 2 diabetes through nutritional counseling. Diabetes Care 2004; 27: 3019
17. Zimmet P, Shaw J, Alberti KG. Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 2003; 20: 693-702
18. Schwarz P et al. Gründung der "Arbeitsgemeinschaft Prävention des Typ-2-Diabetes" der DDG. Diabetes und Stoffwechsel 2003; 12: 296-274
19. Schwarz P. Targeted diabetes prevention in high risk groups: pro. Dtsch Med Wochenschr 2005; 130: 1103
20. M Wenying Y, Lixiang L, Jinwu Q, Zhiqing Y, Haicheng P, Guofeng H. The preventive effect of acanbose and metformin on the IGT population from becoming diabetes mellitus - a 3-year multicenter prospective study. Chin J Endocrinol Metab 2001; 17: 131-136
21. Chiasson JL et al. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin Dependent Diabetes Mellitus. Diabetes Care 1998: 21: 1720-1725